New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:43 EDTAERIAerie Pharmaceuticals price target raised to $36 from $27 at RBC Capital
RBC Capital believes that Phase IIb results for Aerie's glaucoma treatment, Roclatan, lower the risks faced by the company. The firm says that the data would be good enough to support approval of the drug if the trial was a Phase III study. It keeps an Outperform rating on the shares.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
14:31 EDTAERIAerie Pharmaceuticals downgraded to Hold from Buy at Needham
Subscribe for More Information
10:11 EDTAERIHigh option volume stocks
High option volume stocks: AERI UEC NUAN DSW CHU SVU PII ACTG GIMO JNPR
10:00 EDTAERIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:20 EDTAERIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
08:07 EDTAERIAerie Pharmaceuticals still has significant opportunity, says Stifel
Subscribe for More Information
07:15 EDTAERIAerie Pharmaceuticals weakness overdone, says Brean Capital
Subscribe for More Information
06:36 EDTAERIAerie Pharmaceuticals downgraded to Hold from Buy at Canaccord
Canaccord downgraded Aerie Pharmaceuticals to Hold after Rhopressa, the company's lead glaucoma candidate, missed the primary endpoint in a Phase 3 trial. Note Cantor Fitzgerald also downgraded shares this morning.
06:33 EDTAERIAerie Pharmaceuticals downgraded to Hold from Buy at Cantor
Subscribe for More Information
April 23, 2015
19:16 EDTAERIOn The Fly: After Hours Movers
Subscribe for More Information
16:13 EDTAERIAerie Pharmaceuticals reports Rhopressa Phase 3 did not meet primary endpoint
Subscribe for More Information
April 16, 2015
08:25 EDTAERIOutlook for Aerie Pharmaceuticals trial positive, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use